Paula Zusi
Ms. Zusi's term ended with her resignation from the Board, effective as of the conclusion of the Annual Meeting.
Highest-materiality recent filing
Olaplex Q1 net sales up 2.5% to $99.4M but swings to net loss of $5.3M; adjusted EBITDA falls 26.1%
Net sales up 2.5% to $99.4M; Specialty Retail -13.3% to $33.4M, Professional +12.3% to $38.8M, DTC +13.8% to $27.2M.
Olaplex to be acquired by Henkel for $2.06 per share ($1.4B equity value)
Cash consideration of $2.06/share represents ~55% premium over 3/25/26 close and ~45% premium over 30-day VWAP.
Olaplex Q4 sales up 4.3% to $105.1M; net loss widens to $13.1M from $8.8M
Q4 net loss of $13.1M ($0.02 diluted EPS loss) vs $8.8M loss ($0.01 loss) a year ago.
Olaplex Q3 net sales fall 3.8%, net income down 24.8%; reaffirms guidance
Net sales $114.6M, down 3.8% YoY; US sales -14.6%, international +7.1%.
Olaplex acquires biotech firm Purvala Bioscience for $10.5M in cash
Purchase price $10.5M, subject to adjustments; $1.05M escrowed for 15 months for indemnification.
Olaplex Q2 net loss $7.7M vs prior-year income; revenue up 2.3% to $106.3M
Net loss of $7.7M (diluted EPS -$0.01) vs net income of $5.8M ($0.01) in Q2 2024.
Olaplex Holdings Elects Jerome Griffith as Class I Director
Jerome Griffith, age 67, elected to the board effective July 20, 2025, with a term expiring at the 2028 annual meeting.
Olaplex holds 2025 annual meeting; director Paula Zusi departs, three Class I directors elected
Paula Zusi's term ended after not being nominated for re-election at the June 10 annual meeting.
Ms. Zusi's term ended with her resignation from the Board, effective as of the conclusion of the Annual Meeting.
Max materiality 0.95 · Median 0.62 · Most common event earnings